{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:25:37Z","timestamp":1775064337953,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the 14th Youth Development Fund by The First Hospital of Jilin University","award":["JDYY14202329"],"award-info":[{"award-number":["JDYY14202329"]}]},{"name":"Norman Bethune Special Fund by The First Hospital of Jilin University","award":["20210101247JC"],"award-info":[{"award-number":["20210101247JC"]}]},{"name":"the Science and Technology Innovation Platform of Jilin Province","award":["YDZJ202202CXJD050"],"award-info":[{"award-number":["YDZJ202202CXJD050"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93771-2","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T07:45:25Z","timestamp":1742456725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["High disease activity correlate with decreased serum calcium in systemic lupus erythematosus"],"prefix":"10.1038","volume":"15","author":[{"given":"Xue","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"93771_CR1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/rheumatology\/keac334","volume":"62","author":"CS Yee","year":"2023","unstructured":"Yee, C. S. et al. The BILAG-2004 index is associated with development of new damage in SLE. Rheumatol. (Oxford). 62, 668\u2013675 (2023).","journal-title":"Rheumatol. (Oxford)"},{"key":"93771_CR2","doi-asserted-by":"crossref","first-page":"152103","DOI":"10.1016\/j.semarthrit.2022.152103","volume":"57","author":"LW Garcia","year":"2022","unstructured":"Garcia, L. W. et al. The new EULAR\/ACR 2019 SLE classification criteria: a predictor of long-term outcomes. Semin Arthritis Rheum. 57, 152103 (2022).","journal-title":"Semin Arthritis Rheum."},{"key":"93771_CR3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian, J., Zhang, D., Yao, X., Huang, Y. & Lu, Q. Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. Ann. Rheum. Dis. 82, 351\u2013356 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"93771_CR4","first-page":"103428","volume":"25","author":"LS In\u00eas","year":"2023","unstructured":"In\u00eas, L. S. et al. What is the best instrument to measure disease activity in SLE \u2013 SLE-DAS vs easy BILAG. Autoimmun. Rev. 25, 103428 (2023).","journal-title":"Autoimmun. Rev."},{"key":"93771_CR5","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/keac610","volume":"62","author":"M Barber","year":"2023","unstructured":"Barber, M., Falasinnu, T., Goldman, R. R. & Clarke, A. E. The global epidemiology of SLE: narrowing the knowledge gaps. Rheumatol. (Oxford). 62, i4\u2013i9 (2023).","journal-title":"Rheumatol. (Oxford)"},{"key":"93771_CR6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1042\/CS20080540","volume":"118","author":"CL Basiglio","year":"2009","unstructured":"Basiglio, C. L. et al. Complement activation and disease: protective effects of hyperbilirubinaemia. Clin. Sci. (Lond). 118, 99\u2013113 (2009).","journal-title":"Clin. Sci. (Lond)"},{"key":"93771_CR7","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00011-023-01793-1","volume":"72","author":"DC Wang","year":"2023","unstructured":"Wang, D. C. et al. Systemic lupus erythematosus with high disease activity identification based on machine learning. Inflamm. Res. 72, 1909\u20131918 (2023).","journal-title":"Inflamm. Res."},{"key":"93771_CR8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.it.2020.06.012","volume":"41","author":"M Vaeth","year":"2020","unstructured":"Vaeth, M., Kahlfuss, S. & Feske, S. CRAC channels and calcium signaling in T cell-mediated immunity. Trends Immunol. 41, 878\u2013901 (2020).","journal-title":"Trends Immunol."},{"key":"93771_CR9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/imm.13538","volume":"167","author":"PS Giri","year":"2022","unstructured":"Giri, P. S., Bharti, A. H., Begum, R. & Dwivedi, M. Calcium controlled NFATc1 activation enhances suppressive capacity of regulatory T cells isolated from generalized vitiligo patients. Immunology 167, 314\u2013327 (2022).","journal-title":"Immunology"},{"key":"93771_CR10","doi-asserted-by":"crossref","first-page":"109603","DOI":"10.1016\/j.celrep.2021.109603","volume":"36","author":"B Wu","year":"2021","unstructured":"Wu, B. et al. NKD2 mediates stimulation-dependent ORAI1 trafficking to augment Ca entry in T cells. Cell. Rep. 36, 109603 (2021).","journal-title":"Cell. Rep."},{"key":"93771_CR11","doi-asserted-by":"crossref","first-page":"e2010789118","DOI":"10.1073\/pnas.2010789118","volume":"118","author":"Y Shen","year":"2021","unstructured":"Shen, Y., Thillaiappan, N. B. & Taylor, C. W. The store-operated Ca2+ entry complex comprises a small cluster of STIM1 associated with one Orai1 channel. Proc. Natl. Acad. Sci. U S A. 118, e2010789118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"93771_CR12","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.immuni.2021.11.006","volume":"54","author":"R Newman","year":"2021","unstructured":"Newman, R. & Tolar, P. Chronic calcium signaling in IgE+ B cells limits plasma cell differentiation and survival. Immunity 54, 2756\u20132771e10 (2021).","journal-title":"Immunity"},{"key":"93771_CR13","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/art.42482","volume":"75","author":"DM Ferri","year":"2023","unstructured":"Ferri, D. M. et al. Elevated levels of Interferon-\u03b1 act directly on B cells to breach multiple tolerance mechanisms promoting autoantibody production. Arthritis Rheumatol. 75, 1542\u20131555 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"93771_CR14","doi-asserted-by":"crossref","first-page":"850759","DOI":"10.3389\/fimmu.2022.850759","volume":"13","author":"JA Mughales","year":"2022","unstructured":"Mughales, J. A. Anti-Nuclear antibodies patterns in patients with systemic lupus erythematosus and their correlation with other diagnostic immunological parameters. Front. Immunol. 13, 850759 (2022).","journal-title":"Front. Immunol."},{"key":"93771_CR15","doi-asserted-by":"crossref","first-page":"103883","DOI":"10.1016\/j.ebiom.2022.103883","volume":"77","author":"J Han","year":"2022","unstructured":"Han, J. et al. Fucosylation of anti-dsDNA IgG1 correlates with disease activity of treatment-na\u00efve systemic lupus erythematosus patients. EBioMedicine 77, 103883 (2022).","journal-title":"EBioMedicine"},{"key":"93771_CR16","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","volume":"391","author":"ZW Lai","year":"2018","unstructured":"Lai, Z. W. et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial. Lancet 391, 1186\u20131196 (2018).","journal-title":"Lancet"},{"key":"93771_CR17","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.3390\/ijms24076578","volume":"24","author":"D Accapezzato","year":"2023","unstructured":"Accapezzato, D. et al. Advances in the pathogenesis and treatment of systemic lupus erythematosus. Int. J. Mol. Sci. 24, 6578 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"93771_CR18","doi-asserted-by":"crossref","first-page":"102979","DOI":"10.1016\/j.jaut.2022.102979","volume":"137","author":"SL Coss","year":"2023","unstructured":"Coss, S. L. et al. The complement system and human autoimmune diseases. J. Autoimmun. 137, 102979 (2023).","journal-title":"J. Autoimmun."},{"key":"93771_CR19","doi-asserted-by":"crossref","first-page":"103446","DOI":"10.1016\/j.autrev.2023.103446","volume":"23","author":"A Mathian","year":"2024","unstructured":"Mathian, A., Arnaud, L. & Irastorza, G. R. Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission. Autoimmun. Rev. 23, 103446 (2024).","journal-title":"Autoimmun. Rev."},{"key":"93771_CR20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/rheumatology\/keac355","volume":"62","author":"F Buttgereit","year":"2022","unstructured":"Buttgereit, F. & Kvien, T. K. Controversies in rheumatology: maintenance therapy with low-dose glucocorticoids in rheumatoid arthritis. Rheumatol. (Oxford). 62, 35\u201341 (2022).","journal-title":"Rheumatol. (Oxford)"},{"key":"93771_CR21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1210\/endrev\/bnad016","volume":"44","author":"R Pofi","year":"2023","unstructured":"Pofi, R., Caratti, G., Ray, D. W. & Tomlinson, J. W. Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad. Endocr. Rev. 44, 975\u20131011 (2023).","journal-title":"Endocr. Rev."},{"key":"93771_CR22","doi-asserted-by":"crossref","first-page":"102861","DOI":"10.1016\/j.jaut.2022.102861","volume":"132","author":"H Lou","year":"2022","unstructured":"Lou, H., Ling, G. & Cao, X. Autoantibodies in systemic lupus erythematosus: from immunopathology to therapeutic target. J. Autoimmun. 132, 102861 (2022).","journal-title":"J. Autoimmun."},{"key":"93771_CR23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-Severely active systemic lupus erythematosus. Arthritis Rheum. 62, 222\u2013233 (2010).","journal-title":"Arthritis Rheum."},{"key":"93771_CR24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","volume":"78","author":"S Oon","year":"2019","unstructured":"Oon, S. et al. Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of Belimumab in systemic lupus erythematosus. Ann. Rheum. Dis. 78, 629\u2013633 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"93771_CR25","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kez191","volume":"58","author":"I Parodis","year":"2019","unstructured":"Parodis, I. et al. Predictors of low disease activity and clinical remission following Belimumab treatment in systemic lupus erythematosus. Rheumatol. (Oxford). 58, 2170\u20132176 (2019).","journal-title":"Rheumatol. (Oxford)"},{"key":"93771_CR26","doi-asserted-by":"crossref","first-page":"103165","DOI":"10.1016\/j.autrev.2022.103165","volume":"21","author":"B Sam\u00f5es","year":"2022","unstructured":"Sam\u00f5es, B., Zen, M., Aleixo, J. A., Gatto, M. & Doria, A. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus. Autoimmun. Rev. 21, 103165 (2022).","journal-title":"Autoimmun. Rev."},{"key":"93771_CR27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-immunol-032414-112212","volume":"33","author":"S Feske","year":"2015","unstructured":"Feske, S., Wulff, H. & Skolnik, E. Y. Ion channels in innate and adaptive immunity. Annu. Rev. Immunol. 33, 291\u2013353 (2015).","journal-title":"Annu. Rev. Immunol."},{"key":"93771_CR28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12016-021-08898-7","volume":"63","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Xiao, S., Xia, Y. & Wang, H. The therapeutic strategies for SLE by targeting Anti-dsDNA antibodies. Clin. Rev. Allergy Immunol. 63, 152\u2013165 (2022).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"93771_CR29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood.2022019361","volume":"142","author":"A Java","year":"2023","unstructured":"Java, A., Atkinson, J., Hu, Z. & Pozzi, N. Mutations in atypical hemolytic uremic syndrome provide evidence for the role of calcium in complement factor I. Blood 142, 607\u2013610 (2023).","journal-title":"Blood"},{"key":"93771_CR30","doi-asserted-by":"crossref","unstructured":"Java, A., Atkinson, J. & Salmon, J. Defective complement inhibitory function predisposes to renal disease. Annu. Rev. Med. 2013:64307\u201364324 .","DOI":"10.1146\/annurev-med-072211-110606"},{"key":"93771_CR31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/rheumatology\/keac225","volume":"62","author":"L Ji","year":"2022","unstructured":"Ji, L. et al. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. Rheumatol. (Oxford). 62, 181\u2013189 (2022).","journal-title":"Rheumatol. (Oxford)"},{"key":"93771_CR32","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/rheumatology\/keab501","volume":"61","author":"CM Grajales","year":"2022","unstructured":"Grajales, C. M. et al. Serological abnormalities that predict progression to systemic autoimmune rheumatic diseases in antinuclear antibody\u2013positive individuals. Rheumatol. (Oxford). 61, 1092\u20131105 (2022).","journal-title":"Rheumatol. (Oxford)"},{"key":"93771_CR33","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1136\/annrheumdis-2019-216259","volume":"80","author":"DS Pisetsky","year":"2021","unstructured":"Pisetsky, D. S., Spencer, D. M., Rovin, B. & Lipsky, P. E. Role of ANA testing in the classification of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 80, e124 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"93771_CR34","doi-asserted-by":"crossref","first-page":"629807","DOI":"10.3389\/fimmu.2021.629807","volume":"12","author":"SK Datta","year":"2021","unstructured":"Datta, S. K. Harnessing tolerogenic histone peptide epitopes from nucleosomes for selective Down-Regulation of pathogenic autoimmune response in lupus (Past, present, and Future). Front. Immunol. 12, 629807 (2021).","journal-title":"Front. Immunol."},{"key":"93771_CR35","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.3390\/cells11244032","volume":"11","author":"M Schaaf","year":"2022","unstructured":"Schaaf, M. & Meijer, O. C. Immune modulations by glucocorticoids: from molecular biology to clinical research. Cells 11, 4032 (2022).","journal-title":"Cells"},{"key":"93771_CR36","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","volume":"373","author":"PJ Barnes","year":"2009","unstructured":"Barnes, P. J. & Adcock, I. M. Glucocorticoid resistance in inflammatory diseases. Lancet 373, 1905\u20131917 (2009).","journal-title":"Lancet"},{"key":"93771_CR37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.lfs.2018.08.038","volume":"209","author":"H Gao","year":"2018","unstructured":"Gao, H. et al. Molecular mechanisms of glucocorticoid resistance in systemic lupus erythematosus: A review. Life Sci. 209, 383\u2013387 (2018).","journal-title":"Life Sci."},{"key":"93771_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cytogfr.2019.04.003","volume":"50","author":"S Mathavarajah","year":"2019","unstructured":"Mathavarajah, S., Salsman, J. & Dellaire, G. An emerging role for calcium signalling in innate and autoimmunity via the cGAS-STING axis. Cytokine Growth Factor. Rev. 50, 43\u201351. https:\/\/doi.org\/10.1016\/j.cytogfr.2019.04.003 (2019).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"93771_CR39","doi-asserted-by":"crossref","first-page":"e202104007","DOI":"10.1083\/jcb.202104007","volume":"220","author":"E Zomot","year":"2021","unstructured":"Zomot, E., Cohen, H. A., Dagan, I., Militsin, R. & Palty, R. Bidirectional regulation of calcium release-activated calcium (CRAC) channel by SARAF. J. Cell. Biol. 220, e202104007 (2021).","journal-title":"J. Cell. Biol."},{"key":"93771_CR40","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1172\/JCI129018","volume":"130","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. E4BP4-mediated Inhibition of T follicular helper cell differentiation is compromised in autoimmune diseases. J. Clin. Invest. 130, 3717\u20133733 (2020).","journal-title":"J. Clin. Invest."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93771-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93771-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93771-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T07:47:21Z","timestamp":1742456841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93771-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93771"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93771-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9588"}}